Related references
Note: Only part of the references are listed.Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention
Bryan D. Fleming et al.
HEPATOLOGY (2020)
A novel approach to assess domain specificity of anti-drug antibodies to moxetumomab pasudotox, an immunotoxin with two functional domains
Inna Vainshtein et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2020)
Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia
Robert J. Kreitman et al.
ONCOLOGIST (2020)
Deimmunizing substitutions in Pseudomonas exotoxin domain III perturb antigen processing without eliminating T-cell epitopes
Daniel L. Moss et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Moxetumomab pasudotox: A first-in-class treatment for hairy cell leukemia
Karen M. Fancher et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Depletion of PD-1-positive cells ameliorates autoimmune disease
Peng Zhao et al.
NATURE BIOMEDICAL ENGINEERING (2019)
Targeted Diphtheria Toxin-Based Therapy: A Review Article
Fatemeh Shafiee et al.
FRONTIERS IN MICROBIOLOGY (2019)
Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease
Christoph Groth et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval
Adam Yuh Lin et al.
BLOOD ADVANCES (2019)
Phase I/II study of mesothelin-targeted immunotoxin LMB-100 with nab-paclitaxel for patients with advanced pancreatic adenocarcinoma
Christine C. Alewine et al.
CANCER RESEARCH (2019)
Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins
Ronit Mazor et al.
AMERICAN JOURNAL OF PATHOLOGY (2018)
Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin
Emily M. King et al.
JOURNAL OF IMMUNOLOGY (2018)
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Robert J. Kreitman et al.
LEUKEMIA (2018)
Improving the In Vivo Efficacy of an Anti-Tac (CD25) Immunotoxin by Pseudomonas Exotoxin A Domain II Engineering
Gilad Kaplan et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity
Ronit Mazor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Moxetumomab Pasudotox: First Global Approval
Sohita Dhillon
DRUGS (2018)
Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo
Ronit Mazor et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2017)
Role of HLA-DP in the Presentation of Epitopes from the Truncated Bacterial PE38 Immunotoxin
Ronit Mazor et al.
AAPS JOURNAL (2017)
Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein
B. A. Krishna et al.
NATURE COMMUNICATIONS (2017)
Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38
Ronit Mazor et al.
CELLULAR IMMUNOLOGY (2017)
Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease
A. S. Strik et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity
Robert J. Kreitman et al.
CLINICAL CANCER RESEARCH (2016)
Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist
David A. Khan
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2016)
Immunogenicity of therapeutic recombinant immunotoxins
Ronit Mazor et al.
IMMUNOLOGICAL REVIEWS (2016)
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Raffit Hassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox
Amy K. Schneider et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2016)
Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy
Frieder Bauss et al.
MOLECULAR ONCOLOGY (2016)
Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity
Ronit Mazor et al.
ONCOTARGET (2016)
Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
Y. Andersson et al.
BRITISH JOURNAL OF CANCER (2015)
Enzyme Replacement Therapies and Immunogenicity in Lysosomal Storage Diseases: Is There a Pattern?
Paul Harmatz
CLINICAL THERAPEUTICS (2015)
Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A
Ronit Mazor et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2015)
Bortezomib Reduces Pre-Existing Antibodies to Recombinant Immunotoxins in Mice
Michael L. Manning et al.
JOURNAL OF IMMUNOLOGY (2015)
Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors
Ronit Mazor et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development
Joerg U. Schmohl et al.
TOXINS (2015)
Pseudomonas Exotoxin A: optimized by evolution for effective killing
Marta Michalska et al.
FRONTIERS IN MICROBIOLOGY (2015)
Identification of Immunodominant CD4-Restricted Epitopes Co-Located with Antibody Binding Sites in Individuals Vaccinated with ALVAC-HIV and AIDSVAX B/E
Silvia Ratto-Kim et al.
PLOS ONE (2015)
Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts
Masanori Onda et al.
JOURNAL OF IMMUNOLOGY (2014)
In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer
Kevin Hollevoet et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers
Christine Alewine et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Removing T-cell epitopes with computational protein design
Chris King et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes
Ronit Mazor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
Meghna Jani et al.
RHEUMATOLOGY (2014)
The Role of Mesothelin in Tumor Progression and Targeted Therapy
Zhewei Tang et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2013)
Construction of an Immunotoxin, D2C7-(scdsFv)-PE38KDEL, Targeting EGFRwt and EGFRvIII for Brain Tumor Therapy
Vidyalakshmi Chandramohan et al.
CLINICAL CANCER RESEARCH (2013)
Shaping T Cell - B Cell Collaboration in the Response to Human Immunodeficiency Virus Type 1 Envelope Glycoprotein gp120 by Peptide Priming
N. Kalaya Steede et al.
PLOS ONE (2013)
Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
Raffit Hassan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Immunotoxins: The Role of the Toxin
Antonella Antignani et al.
TOXINS (2013)
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Marcela V. Maus et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease
Yoav H. Messinger et al.
GENETICS IN MEDICINE (2012)
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
Robert J. Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A
Ronit Mazor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes
Wenhai Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A guide to taming a toxin - recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer
John E. Weldon et al.
FEBS JOURNAL (2011)
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes
Masanori Onda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Peptide binding predictions for HLA DR, DP and DQ molecules
Peng Wang et al.
BMC BIOINFORMATICS (2010)
Molecular Determinants of T Cell Epitope Recognition to the Common Timothy Grass Allergen
Carla Oseroff et al.
JOURNAL OF IMMUNOLOGY (2010)
A Recombinant Immunotoxin Targeting CD22 With Low Immunogenicity, Low Nonspecific Toxicity, and High Antitumor Activity in Mice
Johanna K. Hansen et al.
JOURNAL OF IMMUNOTHERAPY (2010)
The immunogenicity of humanized and fully human antibodies Residual immunogenicity resides in the CDR regions
Fiona A. Harding et al.
MABS (2010)
Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell Reservoirs
Edward A. Berger et al.
PLOS PATHOGENS (2010)
Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics
Satoshi Nagata et al.
ADVANCED DRUG DELIVERY REVIEWS (2009)
Aprotease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity
John E. Weldon et al.
BLOOD (2009)
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
Robert J. Kreitman et al.
CLINICAL CANCER RESEARCH (2009)
Pseudomonas exotoxin A: From virulence factor to anti-cancer agent
Philipp Wolf et al.
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY (2009)
Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose
Christine H. Chung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes
Masanori Onda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo
Daniel J. Powell et al.
JOURNAL OF IMMUNOLOGY (2007)
Phase I study of SS1P a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2007)
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition
Silke Meister et al.
CANCER RESEARCH (2007)
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients
Masanori Onda et al.
JOURNAL OF IMMUNOLOGY (2006)
Development of antibodies for cancer therapy
D. K. Wilkins et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2006)
Monitoring of cellular responses after vaccination against tetanus toxoid:: Comparison of the measurement of IFN-γ production by ELISA, ELISPOT, flow cytometry and real-time PCR
J Tassignon et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2005)
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-Cell malignancies
RJ Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Localization of mesothelin in epithelial ovarian cancer
R Hassan et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2005)
Immunogenicity of engineered antibodies
WYK Hwang et al.
METHODS (2005)
Denileukin diftitox: a concise clinical review
JW Eklund et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2005)
Elimination of an immunodominant CD4+ T cell epitope in human IFN-β does not result in an in vivo response directed at the subdominant epitope
VP Yeung et al.
JOURNAL OF IMMUNOLOGY (2004)
Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1
R Hassan et al.
CLINICAL CANCER RESEARCH (2004)
Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2
M Azemar et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Naturally processed chromatin peptides reveal a major autoepitope that primes pathogenic T and B cells of lupus
A Kaliyaperumal et al.
JOURNAL OF IMMUNOLOGY (2002)
ProPred: prediction of HLA-DR binding sites
H Singh et al.
BIOINFORMATICS (2001)
Phase I trial of recombinant immunotoxin anti-Tac(Fv)PE38 (LMB-2) in patients with hematologic malignancies
RJ Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
